Literature DB >> 14726500

Controlling the Toll road to dendritic cell polarization.

Alessandra Mazzoni1, David M Segal.   

Abstract

The activation of dendritic cells (DC) via Toll-like receptors (TLRs) plays a decisive role in shaping the outcome of primary immune responses. Following TLR engagement by microbial products, DC migrate from peripheral tissues to lymphoid organs and up-regulate major histocompatibility complex and costimulatory molecules, acquiring the unique capacity to prime pathogen-specific, naïve T cells. In addition, DC determine the character of the ensuing immune response by secreting cytokines that drive the development of T cells into T helper cell type 1 (Th1), Th2, or T regulatory effector cells. Three major factors influence the pattern of cytokines released by DC and accordingly, the Th balance: the lineage to which DC belong; the maturation stimulus; and inflammatory mediators present at the site of infection. A major focus of this review is the capacity of DC to integrate these factors and elicit distinct classes of immune responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726500     DOI: 10.1189/jlb.1003482

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  61 in total

1.  Crosstalk between PKA and Epac regulates the phenotypic maturation and function of human dendritic cells.

Authors:  Jone Garay; June A D'Angelo; YongKeun Park; Christopher M Summa; Martha L Aiken; Eric Morales; Kamran Badizadegan; Edda Fiebiger; Bonny L Dickinson
Journal:  J Immunol       Date:  2010-08-20       Impact factor: 5.422

2.  Tolerogenic effect of mouse fibroblasts on dendritic cells.

Authors:  Mohsen Khosravi-Maharlooei; MohammadReza Pakyari; Reza B Jalili; Sanam Salimi-Elizei; Jacqueline C Y Lai; Malihesadat Poormasjedi-Meibod; Ruhangiz T Kilani; Jan Dutz; Aziz Ghahary
Journal:  Immunology       Date:  2016-02-08       Impact factor: 7.397

3.  A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo.

Authors:  Austin Pantel; Cheolho Cheong; Durga Dandamudi; Elina Shrestha; Saurabh Mehandru; Luke Brane; Darren Ruane; Angela Teixeira; Leonia Bozzacco; Ralph M Steinman; M Paula Longhi
Journal:  Eur J Immunol       Date:  2011-12-12       Impact factor: 5.532

4.  Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.

Authors:  Geetanjali Agnihotri; Breanna M Crall; Tyler C Lewis; Timothy P Day; Rajalakshmi Balakrishna; Hemamali J Warshakoon; Subbalakshmi S Malladi; Sunil A David
Journal:  J Med Chem       Date:  2011-11-04       Impact factor: 7.446

5.  Bone marrow plasmacytoid dendritic cells can differentiate into myeloid dendritic cells upon virus infection.

Authors:  Elina I Zuniga; Dorian B McGavern; Jose L Pruneda-Paz; Chao Teng; Michael B A Oldstone
Journal:  Nat Immunol       Date:  2004-11-07       Impact factor: 25.606

Review 6.  Effects of flagellin on innate and adaptive immunity.

Authors:  Anna N Honko; Steven B Mizel
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 7.  Structural biology of allergens.

Authors:  Wayne R Thomas; Belinda J Hales; Wendy-Anne Smith
Journal:  Curr Allergy Asthma Rep       Date:  2005-09       Impact factor: 4.806

8.  TLR4 signaling via MyD88 and TRIF differentially shape the CD4+ T cell response to Porphyromonas gingivalis hemagglutinin B.

Authors:  Dalia E Gaddis; Suzanne M Michalek; Jannet Katz
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

Review 9.  Toll-like receptor-independent triggering of dendritic cell maturation by viruses.

Authors:  Carolina B López; Jacob S Yount; Thomas M Moran
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Per a 10 protease activity modulates CD40 expression on dendritic cell surface by nuclear factor-kappaB pathway.

Authors:  C Goel; N Kalra; B S Dwarakanath; S N Gaur; N Arora
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.